935687-49-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzyl 6-aminonicotinate is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of new therapeutic compounds with potential applications in various medical fields.
Used in Agrochemical Synthesis:
Similarly, in the agrochemical industry, Benzyl 6-aminonicotinate is utilized as a starting material, playing a crucial role in the creation of new agrochemicals aimed at enhancing crop protection and yield.
Used in Anti-inflammatory and Analgesic Applications:
Benzyl 6-aminonicotinate is used as an anti-inflammatory and analgesic agent in preclinical studies, demonstrating its potential to alleviate inflammation and pain, which could be beneficial in the treatment of various conditions.
Used in Neurological Disorder Treatment:
With potential applications in the treatment of neurological disorders, Benzyl 6-aminonicotinate is being explored for its capacity to address specific neurological conditions, capitalizing on its pharmacological properties.
Overall, Benzyl 6-aminonicotinate is a versatile chemical intermediate with broad applications across different industries, particularly in the development of pharmaceuticals and agrochemicals, and holds promise for future therapeutic advancements.

InChI:InChI=1/C13H12N2O2/c14-12-7-6-11(8-15-12)13(16)17-9-10-4-2-1-3-5-10/h1-8H,9H2,(H2,14,15)

Upstream product

• 3167-49-5 6-aminonicotinic acid 
• 100-51-6 benzyl alcohol 
• 1072-97-5 5-bromo-2-pyridylamine 
• 124-38-9 carbon dioxide 
• 100-39-0 benzyl bromide 

Downstream Products

• 1215198-26-7 (S)-benzyl 6-(3-cyclopentyl-2-(2-methyl-4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1215198-50-7 (S)-benzyl 6-(3-cyclopentyl-2-(4-(ethylsulfonyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1215197-09-3 (S)-benzyl 6-(3-cyclopentyl-2-(4-(methylsulfonyl)-1H-pyrazol-1-yl)propanamido)nicotinate 
• 1215197-25-3 (S)-benzyl 6-(3-cyclopentyl-2-(4-(methylsulfonyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1215197-82-2 (S)-benzyl 6-(3-cyclopentyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-1yl)propanamido)nicotinate 
• 1215197-90-2 (S)-benzyl 6-(3-cyclopentyl-2-(4-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)propanamido)nicotinate 
• 1215198-24-5 (S)-benzyl 6-(3-cyclohexyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1235443-33-0 (S)-benzyl 6-(2-(2-oxo-5-(trifluoromethyl)pyrazin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinate 
• 1235443-35-2 (S)-benzyl 6-(3-cyclopentyl-2-(2-oxo-5-(trifluoromethyl)pyrazin-1(2H)-yl)propanamido)nicotinate 
• 1235443-45-4 (S)-benzyl 6-(3-cyclobutyl-2-(2-oxo-5-(trifluoromethyl)pyrazin-1(2H)-yl)propanamido)nicotinate 
• 3167-49-5 6-aminonicotinic acid 
• 1215197-37-7 (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid 
• 1215198-58-5 (S)-benzyl 6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinate 
• 1416810-55-3 C₂₂H₁₆ClN₃O₃ 

Relevant academic research and scientific papers

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl) propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus

Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. Systemically acting glucokinase activators (liver and pancreas) have bee

PRODRUGS OF OPIOIDS AND USES THEREOF

The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.

Substituted Pyrazinone Amides

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variables R1, R2

Electrocatalytic carboxylation of 2-amino-5-bromopyridine with CO 2 in ionic liquid 1-butyl-3-methyllimidazoliumtetrafluoborate to 6-aminonicotinic acid

A new electrochemical procedure for the electrocatalytic carboxylation of 2-amino-5-bromopyridine with CO2 in ionic liquid, 1-butyl-3-methyllimidazolium tetrafluoborate (BMIMBF4), to 6-aminonicotinic acid was investigated for the first time. The experiments were carried out in three electrodes undivided cell under mild conditions, and the use of volatile and toxic solvents and catalysts, as well as any other additional supporting electrolytes, was avoided. The electrochemical reduction behavior of 2-amino-5-bromopyridine in BMIMBF4 had been studied by cyclic voltammetry with a reduction peak at-1.6V (vs. Ag). 6-Aminonicotinic acid was obtained in 75% yield and 100% selectivity, under the optimized condition. Moreover, the ionic liquid was successfully recycled.

HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS

The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.

Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.